ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer: A Prospective Multicenter Randomized Controlled Clinical Trial
The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of watching and waiting is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or watching and waiting treatment strategy. The researchers will compare the outcomes between the two groups to see if the PFS between the two groups is similar.
• Both genders are eligible; aged between 18-75 years old; have received neoadjuvant chemotherapy;
• Patients with liver metastatic colorectal cancer who have achieved R0 resection according to MDT evaluation (including patients with metastases treated with ablation therapy that achieved similar R0 resection effects);
• Patients with negative ctDNA after surgery;
• ASA grade \<IV and/or ECOG performance status score ≤ 2;
• Have sufficient understanding of the study and voluntarily sign an informed consent form.